The FDA’s Pharmacy Compounding Advisory Committee met to review seven controversial peptide injections and whether compounding pharmacies should be permitted to dispense them.
Peptides are short amino acid chains heavily promoted in wellness and longevity circles for injury recovery, muscle growth, skin health, and metabolism support.
The global peptide market could exceed $295 billion by 2033 if the Trump administration moves forward with relaxing current manufacturing restrictions.
Health Secretary Robert F. Kennedy Jr. has publicly praised the benefits of peptides, including in an interview with Joe Rogan, and has pledged to reverse Biden-era restrictions on compounding pharmacies.
Those prior restrictions effectively pushed peptides into a grey market, with suppliers overseas filling domestic demand and raising serious safety concerns around unvetted injectable substances.
Compounding pharmacies, many of which had sought to capitalize on the GLP-1 boom, are now positioning themselves for what could be a substantial new revenue opportunity in the peptide space.
The advisory panel was widely expected to recommend allowing compounders to produce at least some of the peptides under review before its sessions concluded.
The panel’s recommendations now go to the FDA, which will determine whether to begin a formal approval process that could take anywhere from a few months to over a year.
FDA scientists urged the advisory committee not to approve compounding for any of the seven peptides under review, citing a lack of human safety data to support widespread use.
Some physicians have echoed those concerns, arguing that insufficient research makes these substances too risky for broad public availability at this stage.
Critics have also noted that many of the advisory committee members appointed by Kennedy have documented ties to the peptide industry, raising questions about the objectivity of the review process.
The outcome of the FDA’s final decision will carry significant consequences for compounding pharmacies, wellness businesses, and the millions of Americans already using these substances without regulatory oversight.
